Edinburgh Research Explorer

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

Research output: Contribution to journalArticle

Standard

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. / on behalf of the SUMMIT Investigators.

In: The Lancet, Vol. 387, No. 10030, 30.04.2016, p. 1817-1826.

Research output: Contribution to journalArticle

Harvard

on behalf of the SUMMIT Investigators 2016, 'Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial', The Lancet, vol. 387, no. 10030, pp. 1817-1826. https://doi.org/10.1016/S0140-6736(16)30069-1

APA

on behalf of the SUMMIT Investigators (2016). Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet, 387(10030), 1817-1826. https://doi.org/10.1016/S0140-6736(16)30069-1

Vancouver

on behalf of the SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016 Apr 30;387(10030):1817-1826. https://doi.org/10.1016/S0140-6736(16)30069-1

Author

on behalf of the SUMMIT Investigators. / Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. In: The Lancet. 2016 ; Vol. 387, No. 10030. pp. 1817-1826.